Utah Medical Products, Inc.: UTMD Announces Self-Tender for 20% of Its Shares

Utah Medical Products (UTMD) announced a self-tender offer to repurchase up to 650,000 shares, or 20% of its outstanding shares, at $75.00 per share. This price is 17% higher than the 12-month average and 21% higher than the 2-year average. The offer, starting September 22, is not conditioned on a minimum number of shares. The company's board approved the offer but did not recommend it to stockholders.

Original reporting
Published Sep 15, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 3:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$UTMD
Bullish
high confidence
Mentioned
$UTMD
Relevance
6/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$UTMDBullishMed
01

Why it matters

The self‑tender offers a 17% premium to the 12‑month average price, likely providing short‑term support to the stock.

02

Market read

A micro‑cap buyback at a premium is a notable catalyst for the stock, offering a clear decision point for shareholders.

03

What to watch

Potential dilution of cash reserves and limited free cash flow to sustain future operations.

Relevance 6/10Novelty 6/10Timing: tender offer opens Sep 22, expires Oct 7

Background

Utah Medical Products develops disposable and reusable specialty medical devices for women's health and neonatal care.

Company-level read

Ticker impact

$UTMDBullishHigh confidence
Context

Utah Medical Products announced a self‑tender offer to repurchase up to 20% of its shares at $75 per share.

Expected impact

Potential short‑term price uplift as investors price in the premium buyback.

Evidence & confidence

Buybacks at a premium are uncommon for micro‑caps and signal confidence, likely attracting buying interest.

Market effects

May signal confidence in the medical device sector, potentially benefiting peers.

Limited to US micro‑cap market; no broader regional effect.

Minimal global impact beyond niche investors.

Counterpoint

The premium could be a red flag if management is overvaluing the stock to prop up a weak business.

Key entities

  • Kevin Cornwell

    Chairman & CEO of Utah Medical Products, quoted on the buyback rationale.

Related articles

$UTMDHigh

UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026

UTAH MEDICAL PRODUCTS INC (UTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026 Contact: Brian Koopman (801) 566-1200 October 22, 2026 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] reports third quarter (3Q) and first nine months (9M) of calend

$UTMDHigh

Utah Medical Products, Inc. Commences Tender Offer

Utah Medical Products (UTMD) offers to buy up to 650,000 shares at $75 each, a 17% premium over the 12-month average. The tender offer, approved by the board, aims to provide liquidity. UTMD's H1 2026 sales and profits declined 12% and 13% YoY, with recent EBITDA at $15.7M. CEO Cornwell believes shares are undervalued, citing industry multiples. The offer expires Oct 7 unless extended.

$UTMDMed

UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2026

UTAH MEDICAL PRODUCTS INC (UTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 utmd_ex99z1.htm EXHIBIT 99.1 EXHIBIT 99.1 UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2026 Contact: Brian Koopman (801) 566-1200 July 23, 2026 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] reports second calendar qua

$NVDAMed

Nvidia shareholders beg for Jensen’s return, as Elon Musk cautions ‘critical deals’ will be lost without him

Nvidia shareholders, including Elon Musk, have petitioned for Jensen Huang's return as CEO after his resignation due to an affair with a suspected Chinese spy. Huang built Nvidia into a multi-trillion-dollar company. Colette Kress will serve as interim CEO. Musk warns critical deals may be lost without Huang. Nvidia will conduct an independent investigation.